TDAR assessments


We are delighted that you have chosen the Immuno-Safety Tools module to start or enhance your current educational journey in immuno-safety science. This lecture is one in a series of six providing detailed information on tools currently used to evaluate and characterize the status of the immune system in a preclinical setting and is led by Dr. Carolyne Dumont at Charles River. Please review the learning objectives below for more information on what you will learn in this lecture.
If you are new to HESI and would like to learn more about our organization, please take a moment to visit our website at

Target Audience

This course is intended for the science professional or graduate student looking to learn the fundamental science and key considerations that are examined in immune safety assessment. The advanced topics offered in this module are intended to take a deeper dive into specific scientific areas. These courses are recommended for the more experienced scientist with a firm grasp of the information highlighted in the introduction module.    

Learning Objectives

The learner will understand:
  • How or when should TDAR be integrated during your preclinical drug development safety studies. 
  • Experimental considerations and limitations to be expected. 
  • What do TDAR effects mean for safety interpretation. 

Additional Information

PDF icon TDAR assessments slide deck - Dumont1.38 MB
Course summary
Available credit: 
  • 1.00 Participation
Course opens: 
Course expires: 

Lectures in this module

Clinical pathology in preclinical immuno-safety assessment
Immunopathology: Evaluation from Discovery to Safety Assessment
TDAR assessments
Cytokine Release Syndrome (CRS)
Systems biology applied to immune safety
Carolyne Dumont, BSc, DABT
Charles River Laboratories

Available Credit

  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

This platform, Ethos CE, works with most modern web browsers (e.g., Chrome, Internet Explorer, MS Edge, Safari). Contact if you are having any difficulties with this platform.